IDO1 and ovarian cancer: In addition, Inaba et al confirmed that treatment with 1-MT, the inhibitor of IDO1, combined with paclitaxel congenially prolonged mouse survival compared to treatment with paclitaxel alone in an IDO1 high expressing ovarian cancer peritoneal carcinomatosis female C57BL/6 mice [24].